[1] LI Jiang XU BinQIAO Zhi TAN Longwang,.Clinical Study on The Effect of Qiangji Recipe on Th17 Cells and Related Factors IL-6 and IL-23 in Patients with Ankylosing Spondylitis [J]. Journal of Shaanxi University of Traditional Chinese Medicine, 2022, (01): 88-92. [doi: 10.13424/j.cnki.jsctcm.2022.01.019]
Clinical Study on The Effect of Qiangji Recipe on Th17 Cells and Related Factors IL-6 and IL-23 in Patients with Ankylosing Spondylitis
- Article number:
- 2096-1340(2022)01-0088-05
- ZTFLH:
- R289
- Code:
- A
- Abstract:
- Abstract： Objective To observe the efficacy of Professor YANG Yuhuas prescription Qiangji formula in the treatment of ankylosing spondylitis (AS) and its effect on Th17 cells and related factors IL-6 and IL-23 in patients with AS.Methods Patients were divided into the prescription traditional Chinese medicine group and the sulfasalazine control group,which were treated for 2 months respectively.All patients in the traditional Chinese medicine group and the control group were scored for disease activity of ankylosing spondylitis before and after treatment (ASDAS),Creactive protein,ESR and HLAB27 were detected to observe the clinical efficacy of the two groups.Blood samples were taken from all cases before treatment,and the number of Th17 cells was detected by flow cytometry；enzymelinked immunosorbent assay (ELISA) related cytokines IL-6 and IL-23.Blood samples were taken again after 2 months of treatment,and samples were compared and analyzed between groups.Results All indexes and the number of Th17 cells in the two groups decreased significantly before and after treatment (P<0.05),And there was no significant difference between the two groups (P>0-05).Conclusion Professor YANG Yuhuas prescription Qiangji recipe can reduce Th17 cells and related factors IL-6 and IL-23 in patients with AS,so as to play a therapeutic role,and its curative effect is not significantly different from that of sulfasalazine.
References:
［1］Park H，Li Z，Yang XO，et al.A distinct Lineage of CD4 T cells regualate tissue inflammation by producing interleukin 17［J］.Nat Immuno1，2005，6(11):1133-1141.
［2］van der Linden S，Valkenburg HA，Cats A.Evaluation of diagnostic criteria for ankylosing spondylitis.A proposal for modification of the New York criteria［J］.Arthritis Rheum，1984，27(4)：361-368.
［3］Curotto de，Lafaille MA，Lafaille JJ.CD4(+)regulatory T cells in autoimmunity and allergy［J］.Curr Opin Immunol 2002，14:771-778.
［4］Bacchetta R，Gregori S，Roncarolo MG.CD4+ regulatory T cells:mechanisms of induction and effector function［J］.Autoimmun Rev，2005，4(8):491-496.
［5］梅杨.强直性脊柱炎患者外周血Th17/Treg细胞失衡研究［D］.合肥：安徽医科大学，2011.
［6］王翠玲，李开智，崔文.强直性脊柱炎患者外周血Th1，Th17，Treg细胞含量及相关细胞因子表达水平研究［J］.慢性病学杂志，2018，19(9):1154-1156，1160.
［7］王亚芳，王梅，宋爱凤.强直性脊柱炎患者外周血Th17/Treg平衡状态对疾病状况的评估价值［J］.国际检验医学杂志，2020，41(7):842-845.
［8］李文清.强直性脊柱炎患者外周血miR155表达及Th17/Treg平衡的关系［J］.山西医科大学学报，2019，50(2):235-240.
［9］AlvaradoSanchez B，HernandezCastro B，PortalesPerez D，et al.Regulatory T cells in patients with systemic lupus erythematosus［J］.J Autoimmun，2006，27:110-118.
［10］Roncarolo MG，Bacchetta R，Bordignon C，et al.Type 1 T regulatory cells［J］.Immunol Rev，2001，182(1):68-79.
［11］刘小莉，张红梅，唐敏，等.不同疾病分期强直性脊柱炎患者外周血DKK-1、MMP-3、TNF-α和IL-6的表达及治疗前后水平变化［J］.现代免疫学，2020，40(4):300-305.
［12］许甜甜，沈炳香，李向阳，等.强直性脊柱炎的中药使用规律浅析［J］.风湿病与关节炎，2020，9(4):20-23，37.
［13］庞红梅.寒湿痹颗粒治疗类风湿关节炎、强直性脊柱炎和膝骨关节炎中医辨证属寒湿痹阻证的临床疗效［J］.中医临床研究，2014，6(26):87-88.
［14］陈育尧，佟丽，吴启富，等.寒湿痹片对类风湿性关节炎模型大鼠踝关节组织病理改变的影响［J］.浙江中西医结合杂志，2010，20(1):12-14.
［15］杜望磊，李治琴，杨西超，等.白芍总苷治疗强直性脊柱炎临床疗效及对血清炎性因子水平的影响［J］.解放军医药杂志，2019，31(1):87-91.
［16］赵亚男.组蛋白甲基化酶EZH2调控强直性脊柱炎Th17分化及中药干预机制［D］.北京：中国中医科学院，2018.
［17］谭希.补肾强督治偻方有效成分分析以及对IL-23/Th17炎症轴的影响［D］.广州：广州中医药大学，2018.
［18］靳国强，赵蕾，韩宗昌，等.顽痹清丸联合常规西药治疗湿热痹阻证强直性脊柱炎28例临床观察［J］.风湿病与关节炎，2019，8(7):8-12.
［19］刘碧燕.针灸联合常规药物治疗强直性脊柱炎患者的效果［J］.中国当代医药，2019，26(2):21-24，33.
［20］伍伟，何东初.中药熏蒸联合常规西药治疗强直性脊柱炎30例临床观察［J］.风湿病与关节炎，2019，8(12):13-16.
Memo
基金项目：国家自然科学基金项目（81774349）